Please wait a minute...
J Zhejiang Univ (Med Sci)  2019, Vol. 48 Issue (1): 116-120    DOI: 10.3785/j.issn.1008-9292.2019.02.17
    
Research advances on the role of exosomes in chemotherapy resistance of ovarian cancer
SHEN Xiameng(),LYU Weiguo()
Department of Gynecology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Download: HTML( 13 )   PDF(514KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Chemotherapy resistance is one of the biggest challenges in treatment of ovarian cancer. Mounting evidence shows that the exosomes shedding from tumor cells are considered to be involved in chemotherapy resistance of ovarian cancer by enhanced exosomal export of drugs, transferring RNAs or proteins and interfering with the bioactivity of therapeutic anti-tumor antibodies. In this review, we display the correlation between exosomes and chemotherapy resistance of ovarian cancer, the mechanism of exosomes involved in chemotherapy resistance of ovarian cancer, and discuss the potential clinical values of exosomes in chemotherapy resistance of ovarian cancer.



Key wordsOvarian neoplasms/drug therapy      Drug tolerance      Exosomes      Review     
Received: 30 September 2018      Published: 10 May 2019
CLC:  R737.31  
Corresponding Authors: LYU Weiguo     E-mail: 21618360@zju.edu.cn;lbwg@zju.edu.cn
Cite this article:

SHEN Xiameng,LYU Weiguo. Research advances on the role of exosomes in chemotherapy resistance of ovarian cancer. J Zhejiang Univ (Med Sci), 2019, 48(1): 116-120.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2019.02.17     OR     http://www.zjujournals.com/med/Y2019/V48/I1/116


外泌体参与卵巢癌患者对化疗耐药的研究进展

患者对化疗药物耐药是晚期卵巢癌患者治疗失败的主要原因之一。外泌体可能通过作为细胞排出化疗药物的途径、通过其携带耐药相关核酸、蛋白质等内容物及通过中和抗体类药物等方式促进卵巢癌患者对化疗药物耐药的发生和发展。本文阐述了外泌体与卵巢癌患者对化疗药物耐药的相关性、外泌体参与耐药的作用机制及其临床价值,以期为卵巢癌患者对化疗药物耐药机制研究、临床诊断和干预提供新的思路。


关键词: 卵巢肿瘤/药物疗法,  药物耐受性,  外泌体,  综述 
[1]   TORRE L A , TRABERT B , DESANTIS C E , et al . Ovarian cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(4):284-296.
[2]   LENGYEL E . Ovarian cancer development and metastasis[J]. Am J Pathol,2010,177(3):1053-1064.
[3]   RAJA F A , COUNSELL N , COLOMBO N , et al . Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data[J]. Ann Oncol,2013,24(12):3028-3034.
[4]   PAN B T , JOHNSTONE R M . Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor[J]. Cell,1983,33(3):967-978.
[5]   FéVRIER B , RAPOSO G . Exosomes: endosomal-derived vesicles shipping extracellular messages[J]. Curr Opin Cell Biol,2004,16(4):415-421.
[6]   ZHANG F F , ZHU Y F , ZHAO Q N , et al . Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance[J]. Eur J Pharmacol,2014,738:83-90.
[7]   CROW J , ATAY S , BANSKOTA S , et al . Exosomes as mediators of platinum resistance in ovarian cancer[J]. Oncotarget,2017,8(7):11917-11936.
[8]   SAMUEL P , MULCAHY L A , FURLONG F , et al . Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells[J]. Philos Trans R Soc Lond B Biol Sci,2018,373(1737):pii: 20170065.
[9]   SAFAEI R , LARSON B J , CHENG T C , et al . Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells[J]. Mol Cancer Ther,2005,4(10):1595-1604.
[10]   DORAYAPPAN K D P , WANNER R , WALLBILLICH J J , et al . Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins[J]. Oncogene,2018,37(28):3806-3821.
[11]   LOPES-RODRIGUES V , DI L A , SOUSA D , et al . Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells[J]. Biochim Biophys Acta,2016,1860(3):618-627.
[12]   LOPES-RODRIGUES V , DI L A , SOUSA D , et al . Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells[J]. Data Brief,2016,6:1023-1027.
[13]   AU Y C L, CO N N, TSURUGA T , et al . Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1[J]. Nat Commun,2016,7:11150.
[14]   CIRAVOLO V , HUBER V , GHEDINI G C , et al . Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy[J]. J Cell Physiol,2012,227(2):658-667.
[15]   WANG T , NING K , LU T X , et al . Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients[J]. Cancer Sci,2017,108(3):448-454.
[16]   YANG S J , WANG D D , LI J , et al . Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer[J]. Gene,2017,623:5-14.
[17]   NING K , WANG T , SUN X , et al . UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer[J]. J Surg Oncol,2017,115(8):932-940.
[18]   DEL R M, BIASCO E , CRUCITTA S , et al . The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients[J]. Eur Urol,2017,71(4):680-687.
[19]   KATO T , MIZUTANI K , KAMEYAMA K , et al . Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer[J/OL]. Urol Oncol,2015,33(9):385.e15-20.
[20]   YIN J , YAN X , YAO X , et al . Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients[J]. J Cell Mol Med,2012,16(2):337-348.
[21]   MENG X , MüLLER V , MILDE-LANGOSCH K , et al . Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer[J]. Oncotarget,2016,7(13):16923-16935.
[22]   MARLEAU A M , CHEN C S , JOYCE J A , et al . Exosome removal as a therapeutic adjuvant in cancer[J]. J Transl Med,2012,10:134.
[23]   AGRAWAL A K , AQIL F , JEYABALAN J , et al . Milk-derived exosomes for oral delivery of paclitaxel[J]. Nanomedicine,2017,13(5):1627-1636.
[24]   AQIL F , JEYABALAN J , AGRAWAL A K , et al . Exosomal delivery of berry anthocyanidins for the management of ovarian cancer[J]. Food Funct,2017,8(11):4100-4107.
[25]   ALVAREZ-ERVITI L , SEOW Y , YIN H , et al . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes[J]. Nat Biotechnol,2011,29(4):341-345.
[26]   REáTEGUI E , VAN DER VOS K E, LAI C P , et al . Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles[J]. Nat Commun,2018,9(1):175.
[27]   KOJIMA R , BOJAR D , RIZZI G , et al . Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment[J]. Nat Commun,2018,9(1):1305.
[1] Baboo Kalianee Devi, CHEN Zhengyun, ZHANG Xinmei. Progress on medical treatment in the management of adenomyosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 142-147.
[2] WU Binbin, YANG Yi. Biomarkers of cardiac surgery-associated acute kidney injury: a narrative review[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 224-229.
[3] YANG Kun, HU Xiaosheng. Research progress on miR-21 in heart diseases[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 214-218.
[4] XU Li, XU Ming, TONG Xiangmin. Effects of aerobic glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma[J]. J Zhejiang Univ (Med Sci), 2019, 48(2): 219-223.
[5] ZHAO Shihao,ZHANG Xue,KE Yuehai. Progress on correlation between cell senescence and idiopathic pulmonary fibrosis[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 111-115.
[6] SONG Fangjun,GUO Hongtao. Progress on structural biology of voltage-gated ion channels[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 25-33.
[7] SHI Jing,FENG Jue. New inhibitors targeting bacterial RNA polymerase[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 44-49.
[8] SUN Boqiang,WANG Qiongyan,PAN Dongli. Mechanisms of herpes simplex virus latency and reactivation[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 89-101.
[9] HONG Feifan,LI Yuezhou. Application of mechanosensitive channels in sonogenetics[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 34-38.
[10] XIAO Li,TONG Xiaoyong. Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 102-110.
[11] XIANG Yilang,WU Ziheng,ZHANG Hongkun. Progress on in situ fenestration during thoracic endovascular aortic repair[J]. J Zhejiang Univ (Med Sci), 2018, 47(6): 617-622.
[12] CAO Liqin,SHI Jimin. Graft failure in allogeneic hematopoietic stem cell trans-plantation[J]. J Zhejiang Univ (Med Sci), 2018, 47(6): 651-658.
[13] TANG Hexiao,BAI Yuquan,SHEN Wulin,ZHAO Jinping. Research progress on interleukin-6 in lung cancer[J]. J Zhejiang Univ (Med Sci), 2018, 47(6): 659-664.
[14] ZHAO Huihui,TANG Huifang. Research progress on composite animal models of inflammatory bowel disease based on gene knockout[J]. J Zhejiang Univ (Med Sci), 2018, 47(6): 665-670.
[15] YE Jianyu,SUN Ziyu,HU Weiwei. Roles of astrocytes in cerebral infarction and related therapeutic strategies[J]. J Zhejiang Univ (Med Sci), 2018, 47(5): 493-498.